The University of California, Davis has launched the Institute for Psychedelics and Neurotherapeutics to advance basic knowledge about the mechanisms of psychedelics.
Awakn Life Sciences has initiated an investigative study to establish the dissociative effect of a proprietary and patent pending formulation of (S)-ketamine and an optimised route...
Beckley Psytech has announced a new clinical trial investigating its novel formulation of the psychedelic drug DMT for the treatment of depression.
In a new brain-imaging study, UK researchers will explore how DMT impacts brain function, behaviour and well-being.
Biopharmaceutical company, Silo Pharma, has announced plans to study its novel joint homing peptide in the treatment of rheumatoid arthritis.
MAPS has announced further developments in its Phase 3 study of MDMA-assisted therapy for the treatment of PTSD.
Results from a new study suggest that the antidepressant effects of ketamine can be prolonged in people with treatment-resistant depression through computer-based neurocognitive training.
The University of California, Davis (UC Davis) and the University of Colorado Anschutz Medical Campus have received a $2.7m (~£2.15m) grant from the National Institute on...
Last week Italy’s Constitutional Court blocked the country’s campaign calling for the decriminalisation of psychotropic substance cultivation.
UK company Clerkenwell Health is working to develop a gold standard in the delivery of psychedelic care.